Letter From the Editor: From 2003 to Today

Clinical Advances in Hematology & Oncology Volume 14, Issue 9, September 2016   It is mid-August. The air is stifling, dripping, melting—making it almost, but not […]

Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma

Lisly J. Chery, MD, Jose A. Karam, MD, and Christopher G. Wood, MD

  Abstract: The incidence of renal cell carcinoma is increasing, with up to one-third of patients presenting with metastatic disease. Combination therapy is used to prolong […]

The Role of High-Dose Melphalan and Autologous Stem Cell Transplant in the Rapidly Evolving Era of Modern Multiple Myeloma Therapy

Clinical Advances in Hematology & Oncology Volume 14, Issue 9, September 2016 Peter M. Voorhees, MD, and Saad Z. Usmani, MD The authors are affiliated with […]

Zika and the Safety of the US Blood Supply

Michael P. Busch, MD, PhD

  H&O  What exactly is the Zika virus, and when was it discovered? MB The Zika virus was discovered in 1947 in the Zika Forest of […]

Emerging Treatment Options for Carcinoid Syndrome

Clinical Advances in Hematology & Oncology Volume 14, Issue 9, September 2016 Matthew H. Kulke, MD Director, Program in Neuroendocrine and Carcinoid Tumors Senior Physician Dana-Farber […]

Management of Brain Metastases in Breast Cancer

Carey K. Anders, MD

  H&O  How common are brain metastases? CA  Lung cancer, melanoma, and breast cancer are the 3 types of cancers that are most likely to metastasize […]

Consolidation Therapy After Autologous Stem Cell Transplant in Relapsed/Refractory Hodgkin Lymphoma

Clinical Advances in Hematology & Oncology Volume 14, Issue 9, September 2016 Craig H. Moskowitz, MD  Steven A. Greenberg Chair in Lymphoma Research Clinical Director, Division […]

Special Concerns for Survivors of Prostate Cancer

Clinical Advances in Hematology & Oncology Volume 14, Issue 9, September 2016 Andrew C. Peterson, MD Professor of Urologic Surgery Duke University School of Medicine Durham, […]

The Importance of Dose Optimization Prior to Initiation of a Registration Trial

Clinical Advances in Hematology & Oncology Volume 14, Issue 9, September 2016 Nam Atiqur Rahman, PhD Director Division of Clinical Pharmacology V Center for Drug Evaluation […]

Erratum

An article in the July 2016 issue, “Bruton’s tyrosine kinase inhibitors in chronic lymphocytic leukemia and lymphoma” by Gaurav Varma, MSPH, Tyler P. Johnson, MD, and […]

Letter from the Editor: The Campaign Button

Clinical Advances in Hematology & Oncology Volume 14, Issue 8, August 2016   In early June, after the US presidential contest had essentially been narrowed down […]

Trifluridine/Tipiracil and Regorafenib: New Weapons in the War Against Metastatic Colorectal Cancer

Benjamin A. Weinberg, MD, John L. Marshall, MD, and Mohamed E. Salem, MD

  Abstract: Colorectal cancer (CRC) is the second leading cause of cancer-related death in the United States. Approximately 20% of patients have metastatic disease at diagnosis, […]

The Status of Poly(Adenosine Diphosphate-Ribose) Polymerase (PARP) Inhibitors in Ovarian Cancer, Part 1: Olaparib

Rowan E. Miller, MD, and Jonathan A. Ledermann, MD

  Abstract: Poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors have shown promising clinical activity in epithelial ovarian cancer. Following the observation in vitro that PARP inhibition is synthetically […]

Moving Beyond Monotherapy in the Immunotherapeutic Arena: Prospects for Combination Therapies in Lung Cancer

Clinical Advances in Hematology & Oncology Volume 14, Issue 8, August 2016 Lung Cancer in Focus   Scott J. Antonia, MD, PhD Chair of the Thoracic […]

Are We Ready for Precision Medicine in Acute Myeloid Leukemia?

Clinical Advances in Hematology & Oncology Volume 14, Issue 8, August 2016 Advances in LLM   Gail J. Roboz, MD  Professor of Medicine Weill Cornell Medicine […]

Highlights in Kidney Cancer From the 2016 American Society of Clinical Oncology Annual Meeting

Clinical Advances in Hematology & Oncology Volume 14, Issue 8, August 2016 Highlights in Kidney Cancer From the 2016 American Society of Clinical Oncology Annual Meeting […]

The Role of Talimogene Laherparepvec (T-VEC) in the Age of Checkpoint Inhibitors

Clinical Advances in Hematology & Oncology Volume 14, Issue 8, August 2016 Robert H. Andtbacka, MD, CM Associate Professor of Surgery University of Utah Huntsman Cancer […]

Recent Advances in the Management of Myelofibrosis

Clinical Advances in Hematology & Oncology Volume 14, Issue 8, August 2016 Ruben A. Mesa, MD Consultant Hematologist Chair, Division of Hematology & Medical Oncology Deputy […]

Sorafenib in Combination With Transarterial Chemoembolization for the Treatment of Hepatocellular Carcinoma

Clinical Advances in Hematology & Oncology Volume 14, Issue 8, August 2016 Jean-Francois H. Geschwind, MD Chairman, Department of Radiology and Biomedical Imaging Professor of Radiology […]

Back to Archive